<DOC>
	<DOCNO>NCT00659529</DOCNO>
	<brief_summary>The purpose study determine whether sildenafil decrease inflammation CF lung disease .</brief_summary>
	<brief_title>Safety Efficacy Sildenafil Cystic Fibrosis ( CF ) Lung Disease</brief_title>
	<detailed_description>This study open-label study examines use sildenafil ( Revatio ) clinically stable patient mild moderate CF lung disease . The length participation subject approximately 10 week , consist screen visit , study visit initiation study drug subject qualifies , interim visit escalate drug dose , obtain drug level , review concomitant medication assess side effect , visit end therapy period ( reassess inflammatory marker , laboratory study side effect , ) follow-up assessment 2 week subject completion .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Phosphodiesterase Inhibitors</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Confirmed diagnosis CF base follow criterion : Positive sweat chloride ≥60mEq/liter ( pilocarpine iontophoresis ) and/or Genotype two identifiable mutation consistent CF , accompany one clinical feature consistent CF phenotype Male female patient ≥ 12 year age FEV1 ≥ 50 % predict ( Knudson ) 31 Clinically stable without evidence acute upper low respiratory tract infection current pulmonary exacerbation within 14 day prior screen visit Ability reproducibly perform spirometry ( accord ATS criterion ) Ability produce least 1mL sputum spontaneously , willing undergo sputum induction Ability understand sign write informed consent assent comply requirement study Chronic bacterial colonization ( 3 document positive culture prior 2 year least one obtain 3 month prior randomization ) History hypersensitivity sildenafil Use investigational agent within 4week period prior Visit 1 ( Day 0 ) Breastfeeding , pregnant , verbal expression unwillingness practice acceptable birth control method ( abstinence , hormonal barrier method , partner sterilization intrauterine device ) participation study Daily use systemic corticosteroid and/or NSAIDs within 4 week study need use within 72 hour prior screen visit History significant hepatic ( SGOT SGPT &gt; 3 time upper limit normal screening , document biliary cirrhosis , portal hypertension ) , cardiovascular ( history aortic stenosis , coronary artery disease , pulmonary hypertension right ventricular systolic pressure &gt; 55 mmHg lifethreatening arrhythmia ) , neurological ( history stroke ) , hematologic ( history bleed diathesis ) , ophthalmologic ( history retinal impairment nonarteritic ischemic optic neuritis ) renal impairment ( creatinine &gt; 1.8 mg/dL . ) Inability swallow pill Previous lung transplantation Use concomitant nitrate , αblocker , Ca channel blocker Use concomitant medication know potent inhibitor CYP3A4 ( e.g . ketoconazole , itraconazole , ritonavir , clarithromycin , erythromycin , rifampin ) Presence condition abnormality opinion investigator would compromise safety subject quality data Weight le 40 kg History sputum throat swab culture yield Burkholderia cepacia within 2 year screen Resting room air oxygen saturation &lt; 93 % History migraine</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>cystic fibrosis</keyword>
	<keyword>inflammation</keyword>
	<keyword>pH</keyword>
	<keyword>EBC</keyword>
	<keyword>sputum biomarkers</keyword>
	<keyword>phosphodiesterase inhibitor</keyword>
</DOC>